PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-63.84%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-88.24%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-87.91%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-87.91%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-63.84%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
OCF/share CAGR of 53.61% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
53.61%
OCF/share CAGR of 53.61% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
53.61%
3Y OCF/share growth of 53.61% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
35.25%
Net income/share CAGR of 35.25% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
35.25%
5Y net income/share CAGR > 1.5x Biotechnology median of 0.27%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
35.25%
3Y net income/share CAGR of 35.25% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Asset growth of 1280.26% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-28.60%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
50.95%
Debt growth of 50.95% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
47.25%
SG&A growth of 47.25% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.